Stoke Therapeutics (NASDAQ: STOK) officer sells 3,712 shares in tax-driven Form 4

Rhea-AI Filing Summary

Stoke Therapeutics Chief Patient Officer Jason Hoitt reported mandated share sales to cover taxes on vested stock units. On March 17–18, 2026, he sold a total of 3,712 shares of common stock in open-market transactions required to satisfy tax withholding obligations. Sale prices were based on weighted averages, with individual trades occurring in ranges between $30.59 and $33.855 per share. After these transactions, he directly holds 10,276 shares, and no remaining stock options or other derivatives are reported.

Insights

Equity compensation & insider-trading analyst

Tax-driven, issuer-mandated sales; weak signaling value for investors.

Jason Hoitt, Chief Patient Officer of Stoke Therapeutics, sold 3,712 common shares on March 17–18, 2026. Footnotes state these were issuer-mandated sales to cover tax withholding from restricted stock unit vesting, not discretionary profit-taking.

The sales were executed as open-market transactions at weighted-average prices within ranges from $30.59 to $33.855 per share. Following the transactions, Hoitt directly owns 10,276 shares and no derivative positions are listed, indicating his remaining exposure is entirely in common stock.

Because the transactions are tied to equity compensation taxes rather than voluntary portfolio changes, they carry limited informational value about management’s view of the stock. Future company filings may provide additional context on ongoing equity compensation and ownership levels.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoitt Jason

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Patient Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		1,033	D	$32.7394(2)	12,955	D
Common Stock	03/17/2026		S(1)		748	D	$33.3754(3)	12,207	D
Common Stock	03/18/2026		S(1)		1,762	D	$31.2838(4)	10,445	D
Common Stock	03/18/2026		S(1)		139	D	$31.7888(5)	10,306	D
Common Stock	03/18/2026		S(1)		30	D	$32.85	10,276	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Stoke Therapeutics (STOK) disclose for Jason Hoitt?

Stoke Therapeutics disclosed that Chief Patient Officer Jason Hoitt sold 3,712 shares of common stock. The sales occurred on March 17–18, 2026 and were issuer-mandated transactions to satisfy tax withholding obligations from the vesting of restricted stock units.

Why did Jason Hoitt sell Stoke Therapeutics (STOK) shares in March 2026?

According to the disclosure, the sales were issuer-mandated to cover tax withholding liabilities from restricted stock unit vesting. This means shares were automatically sold to pay taxes due on equity compensation, rather than being purely discretionary open-market sales.

How many Stoke Therapeutics (STOK) shares did Jason Hoitt sell and at what prices?

Jason Hoitt sold a total of 3,712 shares of Stoke Therapeutics common stock. The shares were sold in multiple open-market trades at weighted-average prices, with individual transaction price ranges between $30.59 and $33.855 per share as described in the footnotes.

How many Stoke Therapeutics (STOK) shares does Jason Hoitt own after the reported sales?

After the reported transactions, Jason Hoitt directly owns 10,276 shares of Stoke Therapeutics common stock. The Form 4 data also show no remaining derivative securities, so his reported exposure consists solely of these common shares following the tax-related sales.

Were Jason Hoitt’s Stoke Therapeutics (STOK) share sales routine or indicative of a strategic move?

The footnotes describe the sales as issuer-mandated to satisfy tax withholding from restricted stock unit vesting. That framing indicates the transactions are routine, compensation-related events rather than a strategic decision to reduce personal exposure to Stoke Therapeutics stock.

What do the weighted-average prices mean in the Stoke Therapeutics (STOK) insider sale filing?

The reported per-share prices are weighted averages for multiple trades executed within specified ranges. For Jason Hoitt’s sales, individual trades occurred between $30.59 and $33.855 per share, with the averages reflecting the combined prices and sizes of those individual transactions.